Denali Therapeutics Inc. Liquidation Value

Denali Therapeutics (DNLI) is a clinical/early-commercial-stage biopharma with one FDA-approved product (AVLAYAH, accelerated approval) and a pipeline funded primarily by equity offerings and collaboration payments. As of March 31, 2026, total assets were $1.27B against total liabilities of $340M, producing GAAP stockholders' equity of $926M. Under a liquidation lens, recovery to equity is positive but meaningfully below book value.

Asset-side recovery: Cash and cash equivalents ($388M, 100% haircut = $388M recoverable) plus current marketable securities ($600M at ~100% for investment-grade AFS = ~$600M) plus noncurrent marketable securities ($64M, ~100%) yields approximately $1.05B in liquid asset recovery, consistent with management's stated cash/equivalents/marketable securities figure. Restricted cash ($3.1M, 100%) adds nominally. PP&E net book value is $52M (Utah manufacturing build-out and leasehold improvements); at 50-60% recovery that yields $26-31M. Finance lease ROU asset ($48M) is a manufacturing facility — recovery on an illiquid specialized asset in wind-down would be low, likely 20-30% ($10-14M). Operating lease ROU ($18M) has effectively zero liquidation value. Prepaid/other current ($35M) recovers partially (~50%, $18M). Other noncurrent assets ($26M, likely deposits and long-term prepaid) at 50% = $13M. Intangibles ($36M, acquired Q1 2026 per NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1) receive 0% recovery under the lens. Total estimated asset recovery: approximately $1.13-1.14B.

Liability-side at face: Current liabilities of $110M (AP $40M, accrued $70M, current leases ~$10M operating + $0.1M finance) plus noncurrent liabilities of $230M (noncurrent operating lease $25M, noncurrent finance lease $6M, and a significant portion of the $275M Royalty Pharma revenue participation agreement — $200M was received in March 2026 per the filing, with the remaining $75M contingent on EMA approval by 12/31/2029). The Royalty Pharma agreement is not separately XBRL-tagged as a distinct liability line in TAG_CONTEXT; the filing discusses it in MD&A as a royalty financing. If the $200M received is recorded as a liability or deferred revenue obligation (likely as a revenue participation right payable), total liabilities could be substantially higher than the $340M GAAP figure shown. Filing does not separately XBRL-tag the Royalty Pharma liability or deferred revenue from this transaction. Purchase obligations of $109M (manufacturing commitments, off-balance-sheet) would survive wind-down and reduce equity recovery further.

Conclusion: Before accounting for the Royalty Pharma obligation and purchase commitments, indicative net recovery is approximately $790-830M against $926M book equity — a roughly 85-90% recovery ratio. Including the $200M Royalty Pharma proceeds (if recorded as a liability) and $109M purchase obligations, recovery drops toward $480-520M, a ~50-55% ratio to book. The $36M intangible acquired Q1 2026 via non-cash transaction has zero liquidation value, representing an immediate drag. The accumulated deficit stands at $2.18B, consistent with the entity's pre-commercial history. Key change since prior filing (10-K, December 31, 2025): $200M Royalty Pharma closing in March 2026 added substantial cash but layered in a royalty obligation (9.25% of AVLAYAH net sales) and potential conditional payments; the December 2025 follow-on equity offering ($189M net + $12M overallotment in January 2026) also closed, explaining the $182M net increase in cash during Q1 2026.